Eli Lilly and Co
$
115.2
-1.3 (-1.12%)
| Volume: | 9,805,773 | Avg Vol (1m): | 21,435,366 |
| Market Cap $: | 111.79 Bil | Enterprise Value $: | 117.56 Bil |
| P/E (TTM): | 37.28 | P/B: | 12.42 |
| Earnings Power Value | -148.33 |
| Net Current Asset Value | -12.77 |
| Tangible Book | 1.85 |
| Projected FCF | 36.58 |
| Median P/S Value | 64.05 |
| Graham Number | 11.35 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 6/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.63 | ||
| Equity-to-Asset | 0.22 | ||
| Debt-to-Equity | 1.30 | ||
| Debt-to-EBITDA | 2.25 | ||
| Interest Coverage | 23.63 | ||
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 3.50 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.36 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 30.72%
WACC 5.3%
| ||
Profitability & Growth : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 26.18 | ||
| Net Margin % | 13.16 | ||
| ROE % | 26.68 | ||
| ROA % | 7.34 | ||
| ROC (Joel Greenblatt) % | 42.21 | ||
| 3-Year Total Revenue Growth Rate | 7.20 | ||
| 3-Year Total EBITDA Growth Rate | 9.00 | ||
| 3-Year EPS w/o NRI Growth Rate | 11.50 |
» LLY's 30-Y Financials
Financials (Next Earnings Date: 2019-04-30)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:LLY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Major   NAICS : 325412   SIC : 2834 |
| Compare | LSE:AZN NYSE:BMY XPAR:SAN LSE:GSK XTER:BAYN TSE:4503 TSE:4519 TSE:4578 NYSE:ABBV TSE:4568 NYSE:MRK HKSE:01093 TSE:4151 TSE:4528 SHSE:600436 SHSE:600867 SZSE:002422 MIL:REC BOM:500087 BOM:500302 |
| Traded in other countries | LILY34.Brazil LEL.UK |
| Address | Lilly Corporate Center, Indianapolis, IN, USA, 46285 |
| Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 37.28 | ||
| Forward PE Ratio | 20.41 | N/A | |
| PE Ratio without NRI | 37.28 | ||
| Price-to-Owner-Earnings | 98.29 | ||
| PB Ratio | 12.42 | ||
| PS Ratio | 4.84 | ||
| Price-to-Free-Cash-Flow | 47.16 | ||
| Price-to-Operating-Cash-Flow | 21.43 | ||
| EV-to-EBIT | 28.90 | ||
| EV-to-EBITDA | 20.71 | ||
| EV-to-Revenue | 4.79 | ||
| Shiller PE Ratio | 34.82 | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.38 | ||
| Days Inventory | 243.81 | ||
| Days Sales Outstanding | 77.98 | ||
| Days Payable | 80.17 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 2.02 | ||
| Dividend Payout Ratio | 0.72 | ||
| 3-Year Dividend Growth Rate (Per Share) | 4.00 | ||
| Forward Dividend Yield % | 2.24 | N/A | |
| Yield-on-Cost (5-Year) % | 2.30 | ||
| 3-Year Share Buyback Rate | 1.40 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 62.27 | ||
| Price-to-Projected-FCF | 3.15 | ||
| Price-to-Median-PS-Value | 1.80 | ||
| Price-to-Graham-Number | 10.09 | ||
| Earnings Yield (Joel Greenblatt) % | 3.46 | ||
| Forward Rate of Return (Yacktman) % | 0.03 |
More Statistics
| Revenue (TTM) (Mil) $ | 24,555.7 |
| EPS (TTM) $ | 3.09 |
| Beta | 0.54 |
| Volatility % | 16.81 |
| 52-Week Range $ | 77.09 - 132.13 |
| Shares Outstanding (Mil) | 970.42 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |